198 related articles for article (PubMed ID: 35720278)
21. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome
Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
Front Immunol; 2022; 13():842069. PubMed ID: 35281041
[TBL] [Abstract][Full Text] [Related]
22. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
Zhong W; Chen H; Yang J; Huang C; Lin Y; Huang J
BMC Med Genomics; 2023 Oct; 16(1):265. PubMed ID: 37885006
[TBL] [Abstract][Full Text] [Related]
24. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
Front Immunol; 2022; 13():935595. PubMed ID: 35935986
[TBL] [Abstract][Full Text] [Related]
25. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
26. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
Front Immunol; 2022; 13():861328. PubMed ID: 35479084
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
29. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.
Chen X; Tu J; Ma L; Huang Y; Yang C; Yuan X
Int J Gen Med; 2022; 15():3215-3235. PubMed ID: 35342303
[TBL] [Abstract][Full Text] [Related]
31. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
[TBL] [Abstract][Full Text] [Related]
32. Cellular senescence and metabolic reprogramming model based on bulk/single-cell RNA sequencing reveals PTGER4 as a therapeutic target for ccRCC.
Zhou L; Zeng Y; Liu Y; Du K; Luo Y; Dai Y; Pan W; Zhang L; Zhang L; Tian F; Gu C
BMC Cancer; 2024 Apr; 24(1):451. PubMed ID: 38605343
[TBL] [Abstract][Full Text] [Related]
33. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
35. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
36. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
37. A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.
Chen W; Lin W; Wu L; Xu A; Liu C; Huang P
Int J Med Sci; 2022; 19(2):377-392. PubMed ID: 35165523
[No Abstract] [Full Text] [Related]
38. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
39. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma.
Zhao J; Liang J; Yang Y; Sun G; Zhang X; Zhao J; Hu X; Chen J; Zhu S; Ni Y; Zhang Y; Dai J; Wang Z; Wang Z; Zeng Y; Yao J; Chen N; Shen P; Liu Z; Zeng H
Clin Epigenetics; 2022 Aug; 14(1):99. PubMed ID: 35941663
[TBL] [Abstract][Full Text] [Related]
40. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.
Liu L; Jin H; Dong M; Tian J; Li H; Liu Q; Chen Y; Zou Z
Apoptosis; 2022 Dec; 27(11-12):946-960. PubMed ID: 36028785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
